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“Acute kidney dysfunction with no
rejection” is associated with poor renal
outcomes at 2 years post kidney
transplantation
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Abstract
Background: “Acute kidney dysfunction with no rejection” (ADNR) corresponds to acute kidney injury without
histological evidence of acute rejection (AR) in kidney transplant recipients (KTR). The prognosis of ADNR is
unknown.
Methods: From 2007 to 2015, we categorized KTR with for-cause kidney biopsy within the first 12 months post
kidney transplantation (KTx) into ADNR (n = 93) and biopsy-proven AR (n = 22). Controls (C, n = 135) included KTR
with no ADNR or AR within the first 24 months post-KTx. A piecewise linear regression with a single fixed-knot at
12 months served to establish intercepts and slopes of MDRD-eGFR variations from 12 to 24 months. The
percentage of KTR with ≥30% reduction of eGFR from 12 to 24 months was calculated as a surrogate marker of
future graft loss.
Results: The median time for for-cause biopsy was 22 [10–70] and 13 [7–43] days for ADNR and AR, respectively. At
12 months, eGFR was significantly higher in C (57.6 ± 14.9 mL/min/1.73m2) vs. ADNR (43.5 ± 15.4 mL/min/1.73m2,
p < 0.0001) and vs. AR (46.5 ± 15.2 mL/min/1.73m2, p < 0.0065). The proportion of KTR with ≥30% reduction in eGFR
from 12 to 24 months reached 16.3% in C vs. 29.9% in ADNR (p = 0.02) and vs. 15% in AR (not significant).
Conclusions: ADNR is associated with poor outcomes within 2 years post-KTx.
Keywords: Acute kidney dysfunction with no rejection (ADNR), Kidney transplant recipients (KTR), Estimated
glomerular filtration rate (eGFR), Acute rejection (AR), Outcomes
Background
Kidney transplantation (KTx) is currently the best thera-
peutic option for patients suffering from end-stage renal
disease, with reduced all-cause and cardiovascular mor-
tality and improved quality of life as compared to
chronic dialysis [1]. Still, acute rejection (AR) under-
mines the full benefits of KTx [2, 3]. Typically, AR is
suspected when serum creatinine (SCr) rises from indi-
vidual baseline value [4]. Although various non-invasive
approaches are currently under development [2, 5–10],
the gold standard for AR diagnosis still relies on kidney
graft biopsy and Banff classification [11–13]. However, a
significant number of KTR presenting with acute eleva-
tion of SCr show a normal renal histology, with no
biopsy-proven AR. Kurian S.M. and colleagues intro-
duced the concept of “acute dysfunction with no rejec-
tion” (ADNR) in 2014 [10]. To the best of our
knowledge, there is no data concerning the long-term
outcomes of KTR with ADNR, in comparison to (i) KTR
with biopsy-proven AR or (ii) KTR with no acute kidney
injury (AKI) during the follow-up.
In 2016, Clayton P.A. et al. [14] demonstrated that
≥30% decline in estimated glomerular filtration rate
(eGFR) between 12 and 24 months post-KTx is strongly
associated with risks of subsequent death and death-
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censored graft failure among KTR, which advocates for
the use of percentage decline in eGFR as a surrogate
outcome in KTx studies.
Here, we calculated the eGFR at 12 months post-KTx
and the eGFR ≥30% decline between 12 and 24months




All KTx performed from January 2007 to June 2015 were
retrieved from our prospective database at the University
of Liège Hospital (ULiège CHU) in Liège, Belgium. KTx
with primary non-function or BK virus nephropathy
were excluded. Kidney graft biopsies were graded ac-
cording to the Banff 2013 classification [13]. Histological
lesions were scored as discrete variables (from 0 to 3) on
the basis of leukocyte infiltration severity in each com-
ponent: glomeruli (g), peritubular capillaries (ptc), arter-
ies (v), tubules (t), and interstitium (i). Biopsies were
considered normal when there were no tubulitis (t = 0),
no vasculitis (v = 0), no or mild microvascular inflamma-
tion (g + ptc < 2) without circulating donor specific anti-
body (DSA) and no features of a disease process.
Borderline changes were defined as mild to severe tubu-
litis (t > 0) with no to severe interstitial inflammation
(i0–3) not reaching the threshold for acute cellular rejec-
tion definition, and no feature of a specific disease
process. Biopsies diagnosed as cellular AR were defined
as having a Banff score ≥ i2 and ≥ t2 and/or v > 0. Anti-
body mediated AR definition required three criteria: cir-
culating DSA, micro- (g and/or ptc > 0) or macro-
vascular inflammation (v > 0) and evidence of antibody
interaction with the endothelium either as c4d depos-
ition or as at least moderate microvascular inflammation
(g + ptc > =2). All the included biopsies met adequacy
criteria (at least 7 glomeruli and 1 artery) [12]. All the
biopsies performed during the first 12 months post-KTx
were extracted from the database, as well as all individ-
ual creatinine values, and these results were used to
categorize the patients in 2 groups, i.e. AR and ADNR.
All the for-cause biopsies were clinically indicated.
When a KTR received several biopsies in that time
frame, the first adequate graft biopsy within the first 12
months post-KTx was kept for analysis. The ADNR
group included patients with no histological evidence of
AR. The AR group included KTR with biopsy-proven
AR. The control (C) group included KTR with no AKI
over a 24-month follow-up post-KTx and normal renal
histology at 3 months post-KTx (protocol biopsy).
Statistics
The eGFR was determined using the Modification of
Diet in Renal Disease (MDRD) Study equation [15].
MDRD is based on SCr upon the following formula: 175
x SCr (mg/dl)-1.154 x age-0.203 × 0.742 (if woman). Con-
tinuous piecewise linear regression with a fixed knot at
12 months for eGFR versus time were fitted to generate
two regression lines, i.e. one corresponding to the first
12 months post-KTx and one corresponding to the
follow-up between 12 and 24 months post-KTx. The lin-
ear regressions were calculated individually for each pa-
tient and the slopes of the second part of the regression
were used to describe the evolution of eGFR over that
time-frame. The baseline eGFR value (eGFR1Y) was
taken as the predicted value at the knot (12 months).
Likewise, the final eGFR value (eGFR2Y) was calculated
as the value predicted by the second linear regression at
24 months exactly. Percentage decline of eGFR between
12 and 24 months post-KTx was calculated as (eGFR2Y
– eGFR1Y)/eGFR1Y * 100. Finally, the proportion of
KTR showing a ≥ 30% reduction of eGFR between 12
and 24months post-KTx was determined in each group
[14, 16]. Evidence that regressions differed among
groups was obtained by comparing eGFR intercepts and
percentage decline. Analysis of variance (ANOVA) or χ2
test (Fisher’s Exact test for 2 × 2 tables) were used, as ap-
propriate, to compare the clinical characteristics of pa-
tients belonging to the 3 groups. ANOVA was followed
by a post hoc Tukey’s Studentized Range test correcting
for multiple comparisons. All analyses were done with
SAS 9.4 (SAS Institute Inc., Cary, NC, USA).
Results
Out of a cohort of 474 KTR, we identified 250 patients
meeting inclusion criteria that were furthter categorised
into ADNR (n = 93), AR (n = 22) and C (n = 135), as
summarized in Table 1. The median time for the first
clinically indicated graft biopsy was 22 [10–70] and 13
[7–43] days post-KTx for ADNR and AR, respectively.
ADNR group included strictly normal histology (n = 53),
borderline lesions (n = 13), acute tubular necrosis (n =
15), recurrent primary disease (n = 8), and calcineurin
inhibitor (CNI) toxicity (n = 4). Therefore, we divided
the ADNR group in 3 subcategories: strictly normal hist-
ology (n = 53), borderline (n = 13) and heterogeneous
(n = 27). AR were cell- (n = 14) or antibody-mediated
(n = 8). Eleven ADNR patients developed AR within the
24-month follow-up period, in a median time of 250
days [93–545] after ADNR diagnosis. Among these 11
cases, two showed borderline lesions at the first clinically
indicated biopsy. Only one of ADNR biopsies was exclu-
sively indicated for proteinuria > 1 g/g creatininuria. The
mean age (years) at KTx was 50.2 ± 14.2 in ADNR,
47.8 ± 17.8 in AR and 53.6 ± 12.4 in C. The female/male
ratio reached 39.8, 45.5 and 34.1% in ADNR, AR and C,
respectively. There was no significant difference in the
rate of delayed graft function (DGF) among groups. The
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total number of HLA mismatches was significantly
higher in the AR group than in ADNR and C (Table 1).
We used a continuous piecewise linear regression with
a fixed knot at 12 months to split the follow-up time into
two periods: 0–12 months and 12–24months. The
baseline eGFR value is the average value at 12 months
for the intercept of the second part of the regression
line. MDRD value at 12 months were 43.5 ± 15.4 mL/
min/1.73m2 in ADNR, 46.5 ± 15.2 mL/min/1.73m2 in
AR, and 57.6 ± 14.9 mL/min/1.73m2 in C. eGFR at 12
Table 1 Characteristics of the cohort
C n = 135 ADNR n = 93 AR n = 22 p
Recipients Age (years) 53.6 ± 12.4 50.2 ± 14.2 47.8 ± 17.8 0.07
Sex Ratio (%F) 34.1 39.8 45.5 0.48
BMI (kg/m2) 25.1 ± 4.4 25.7 ± 5.2 24.2 ± 5.6 0.35
Dialysis Vintage (days) 581 [260–777] 706 [150–1085] 739 [455–1107] 0.26
Primary renal disease (%) 0.02
Diabetic nephropathy 12.6 7.5 13.6
Hypertension 4.4 3.2 4.6
Glomerulonephritis/vasculitis 26.7 21.5 36.4
Cystic/hereditary/congenital 28.2 18.3 22.7
Interstitial nephritis/pyelonephritis 3.7 17.2 0
Other/unknown etiology 24.4 32.3 22.7
PRA Max
(0–5 /6–84/85–100%)
80/18.5/1.5 75.3/22.6/2.1 63.6/22.7/13.6 0.13
PRA > 20% (%) 11.9 10.8 31.8 0.05
Donors LD (%) 6.7 7.5 22.7 0.09
DCD (%) 25.4 33.7 29.4 0.42
Age (years) 43.01 ± 14.5 46.8 ± 12 47.1 ± 12.9 0.08
Sex Ratio (%F) 45.2 51.6 50 0.62
BMI (kg/m2) 24.4 ± 4.4 25.5 ± 5.2 25.4 ± 5.6 0.18
Transplantation Re-transplant (%) 17.1 20.7 0 0.05
CIT (min) 699 ± 314 752 ± 307 582 ± 367 0.06
HLA MM in toto
A + B + DR (n)
2.7 ± 1.1 2.8 ± 1.1 3.5 ± 0.9*** 0.02
Pre-emptive (%) 8.9 18.3 13.6 0.12
DGF (%) 14.1 26.9 22.7 0.05
Biopsy Time (days) 95 [91–101] 22 [10–70]*** 13 [7–43]*** < 0.01
Serum Creatinine Levels (mg/dL) 1.3 [1.1–1.53] 2.21 [1.65–3.66]*** 2.36 [1.72–3.14]*** < 0.0001
Proteinuria (mg/g creatininuria) 116 [81–174] 437 [168–992]*** 458 [285–1029]*** < 0.001
CNI (%) 99.3 100 100 0.54
CsA (%) 9 8.6 13.6 0.78
MMF derivative (%) 97 97 95.5 0.93
Oral Steroids (%) 99.3 96.8 91 0.09
Induction therapy (%) 0.05
Basiliximab 95.6 93.6 90.9
ATG 2.2 3.2 0
None 1.5 0 9.1
Other 0.7 3.2 0
C controls, ADNR acute dysfunction with no rejection, AR acute rejection, BMI body mass index, PRA panel reactive antibody, LD living donor, DCD donor after
circulatory death, CIT cold ischemic time, HLA MM HLA mismatches, DGF delayed graft function, CNI calcineurin inhibitors, CsA cyclosporine A, MMF
mycophenolate mofetil, ATG antithymocyte globulin. Data are expressed as mean ± standard deviation or as the median and interquartile range (25th–75th
percentile). Analysis of variance (ANOVA) was used to compare the 3 groups. ***p < 0.01 (χ2 test) versus C
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months is significantly different in C versus ADNR (p <
0.0001) and AR (p < 0.0065), while ADNR and AR are
not different from each other (ANOVA, followed by
Tukey’s post hoc test). If we analyzed separately the dif-
ferent ADNR subcategories, in comparison with AR and
C: MDRD values at 12 months were 38.9 ± 15.5 mL/min/
1.73m2 in borderline, 47.7 ± 15.5 mL/min/1.73m2 in het-
erogeneous, 42.7 ± 15.2 mL/min/1.73m2 in strictly nor-
mal histology. eGFR at 12 months is significantly
different (p < 0.05) in C versus AR, strictly normal and
borderline groups, but not versus the heterogeneous
group (ANOVA, followed by Tukey’s post hoc test).
The proportion of KTR presenting with a ≥ 30% reduction
of eGFR from 12 to 24months post-KTx reached 16.3% in
C versus 29.9% in ADNR (p= 0.02) and 15% in AR (not sig-
nificant). In the ADNR subgroups, this proportion reached
30.8% in borderline group, 34.6% in heterogeneous group,
and 27.1% in strictly normal group. There is no statistically
significant difference between these subgroups.
The evolution of eGFR versus time for the different sub-
groups (ADNR, AR and C) is presented in Fig. 1, where
we calculated weekly averaged eGFR-values for the first 3
months and monthly averaged eGFR-values thereafter.
The evolution of time-interval averages of eGFR-values is
plotted for the ADNR-subgroups, together with the AR
and C subgroup, using weekly averages for the first 3
months and monthly averages thereafter (Fig. 2).
Discussion
Our analysis shows that ADNR is associated with a sig-
nificantly lower eGFR at 12 months and greater
proportion of patients with a ≥ 30% reduction of eGFR
from 12 to 24 months post-KTx in comparison to con-
trols. Kurian S.M. and colleagues originally described the
concept of ADNR in the clinical setting of AKI in KTR,
thereby distinguishing AR from ADNR by using a three-
way instead of the two-way classification algorithm (in
which KTR with biopsy-proven AR are classically com-
pared to KTR with stable kidney function) [10]. Doing
so, the authors reported on a 38% prevalence of ADNR
among their 102-patient cohort. Similarly, Rabant M. et
al. [8] categorized their cohort of 281 KTR upon the
histological findings of clinically indicated biopsies.
These for-cause biopsies were clinically indicated for
AKI, proteinuria, identification of de novo DSA, or posi-
tive BK virus viremia. Interestingly, the ADNR group in-
volved 203 cases (72.2%) and included acute tubular
necrosis/minimal lesions, isolated interstitial fibrosis/
tubular atrophy, borderline lesions or a primary diagno-
sis of recurrent disease. Another work was recently pub-
lished by Bloom et al. [17] reported a prevalence of 74%
of ADNR among 204 clinically indicated biopsies. Simi-
larly to our present data, all of these reports emphasized
that ADNR is very frequent in KTR presenting with
AKI. Still, the prognosis of ADNR has not been studied
thus far. Our observations support that the outcomes of
KTR with ADNR appear as poor as AR within the first
2 years post KTx, which should prompt specifically dedi-
cated investigations.
The pathophysiology of ADNR entity remains unclear,
and most probably multifactorial. In our cohort, kidney
graft biopsies were indicated at physicians’ discretion
Fig. 1 Evolution of MDRD-estimated glomerular filtration rate (eGFR). There are 250 kidney transplant recipients categorized into 3 groups on the
basis of histological results of renal graft biopsy: ADNR (acute dysfunction with no rejection, n = 93), AR (acute rejection, n = 22), C (controls, n =
135). The means of MDRD eGFR were exported and plotted against time following kidney transplantation. Data are averaged over 1 week during
the first 3 months, then over 1 month until month 24
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after clinically excluding common causes for AKI in
KTR, like dehydration, CNI toxicity or BK virus ne-
phropathy. Note that we found 53 cases with strictly
normal histology (57%). From a histological point of
view, ADNR is highly heterogeneous. Borderline lesions
belong to ADNR group in our series, as well as in previ-
ous reports [8, 10]. Using microarray profiling, de Freitas
D.G. et al. compared the molecular changes in kidney
graft biopsies with (T-cell-mediated) AR, borderline or
non-rejection [18]. Most borderline cases showed a mo-
lecular phenotype similar to non-rejection, which
prompted the authors to substantially question this am-
biguous “borderline” category in Banff classification [18].
In a pilot study, our team characterized the putative role
of F18 fluorodeoxyglucose positron emission tomography
coupled with computed tomography (18F-FDG PET/CT)
in the diagnostic management of KTR with AKI and sus-
pected AR [5]. The mean standard uptake value (SUV)
of renal grafts with borderline histology was not statisti-
cally different from SUV of control kidneys. Here, only
11 ADNR patients (among whom 2 showed borderline
lesions) eventually developed AR, with a median time of
250 days between ADNR and AR biopsies. The low inci-
dence, as well as the long delay between the events, sug-
gests that ADNR and AR are independent nosological
entities.
Although the histological and molecular phenotyping
of ADNR lesions undoubtedly distinguish it from AR,
our present follow-up study demonstrates that KTR with
ADNR have poor outcomes within the first 2 post-KTx
years. We did not observe significant differences among
ADNR subgroups. One may argue that AKI per se is an
independent risk factor for chronic kidney disease
(CKD), end-stage renal disease (ESRD) and death [19].
Originally considered as fully reversible, AKI is actually
associated with permanent kidney damages [19]. Conse-
quently, the diagnostic and therapeutic management of
KTR with AKI and suspected AR needs to be signifi-
cantly improved. AR is one of the main causes of acute
kidney graft injury and can be efficiently treated by im-
munosuppressive drugs. An early detection of AR is
therefore essential. It currently depends on the follow-
up of serum levels of creatinine, which unfortunately re-
mains an insensitive measure of renal injury. Diagnostic
gold-standard ultimately relies on graft biopsy and Banff
interpretation [11–13]. Because of cost, risks and sam-
pling errors of biopsies [20, 21], non-invasive approaches
are currently under development, like the molecular sig-
nature of CD3ε, IP-10 and 18S RNA levels, the urinary
biomarkers CXCL9/CXCL10, or imaging techniques [2,
5–10]. These may help avoid unnecessary kidney graft
biopsy in patients ultimately presenting with ADNR.
Still, in collaboration with non-transplant nephrologists,
the transplant community needs to develop innovative
therapeutic approaches to prevent the progression from
AKI to CKD and ESRD.
Limitations of our present study include its retrospect-
ive monocentric design based on a limited number of
patients, especially in the AR group (although the
relative incidence of AR in our cohort is similar to pre-
vious larger series). The use of a surrogate outcome, i.e.
≥30% decline in eGFR within a pragmatic 12-month
Fig. 2 Evolution of MDRD-estimated glomerular filtration rate (eGFR). The 250 kidney transplant recipients categorized into 5 groups on the basis
of histological results of renal graft biopsy: borderline (n = 13), heterogeneous (n = 27), strictly normal (n = 53), AR (acute rejection, n = 22), C
(controls, n = 135). The means of MDRD eGFR were exported and plotted against time following kidney transplantation. Data are averaged over 1
week during the first 3 months, then over 1 month until month 24
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timeframe, has been previously strongly associated with
long-term hard outcomes, including graft failure and
death [14]. eGFR decline was shown to be superior to
other classical endpoints, like AR occurrence or SCr
doubling. Note that, in our present study, MDRD equa-
tion was used to estimate GFR, in agreement with previ-
ous reports suggesting that MDRD may perform better
than CKD-EPI in KTR [22].
Conclusions
ADNR occurs frequently and early post-KTx, and is as-
sociated with poor outcomes in KTR. Prospective re-
search needs to focus on the mechanisms of ADNR in
order to improve the diagnostic and therapeutic man-
agement of KTR presenting with AKI.
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